1.  Tandra P, Kallam A, Krishnamurthy J. Identification and management of lymphedema in patients with breast cancer. Journal of oncology practice. 2019 May;15(5):255-62.Available from: (accessed 27.1.2021)
  2.  Rahman M, Mohammed S. Breast cancer metastasis and the lymphatic system. Oncology letters. 2015 Sep 1;10(3):1233-9.Available from: (accessed 27.1.2021)
  3. ↑ Jump up to:3.0 3.1 Breast cancer org. Lymphoedema Available from: (accessed 27.1.2021)
  4. (accessed 27.1.2021)
  5.  Aoishi Y, Oura S, Nishiguchi H, Hirai Y, Miyasaka M, Kawaji M, Shima A, Nishimura Y. Risk factors for breast cancer-related lymphedema: correlation with docetaxel administration. Breast Cancer. 2020 Sep;27(5):929-37.Available from: (accessed 27.1.2021)
  6.  Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Molecular cancer therapeutics. 2005 Oct 1;4(10):1495-504.Available from: 27.1.2021)
  7.  Lu SR, Hong RB, Chou W, Hsiao PC. Role of physiotherapy and patient education in lymphedema control following breast cancer surgery. Therapeutics and clinical risk management. 2015;11:319.Available from: 28.1.2021)
  8.  Ezzo J, Manheimer E, McNeely ML, Howell DM, Weiss R, Johansson KI, Bao T, Bily L, Tuppo CM, Williams AF, Karadibak D. Manual lymphatic drainage for lymphedema following breast cancer treatment. Cochrane Database of Systematic Reviews. 2015(5).Available from: (accessed 27.1.2021)
  9.  Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-Grant L, Bryan CJ, Williams-Smith CT, Greene QP. Weight lifting in women with breast-cancer–related lymphedema. New England Journal of Medicine. 2009 Aug 13;361(7):664-73.Available from: (accessed 28.1.2021)